Assignee
Hansa Biopharma AB
SE·6 granted patents·9 pending applications·16 citations·filing 2020–2025
Top patents by PatentIndex Score
15 records- 0194US11214784B2Cysteine proteaseHansa Biopharma AB·Filed 2020·Granted Jan 4, 2022·7 cites·10 claims
- 0293US11667905B2Cysteine proteaseHansa Biopharma AB·Filed 2021·Granted Jun 6, 2023·5 cites·21 claims
- 0392US11524057B2Cysteine proteaseHansa Biopharma AB·Filed 2020·Granted Dec 13, 2022·4 cites·9 claims
- 0483US12359183B2Cysteine proteaseHansa Biopharma AB·Filed 2023·Granted Jul 15, 2025·0 cites·5 claims
- 0581US2025304937A1Cysteine proteaseHansa Biopharma AB·Filed 2025·Application pending·0 cites
- 0673US2026000739A1Method for improving the benefit to a subject of a therapy or therapeutic agentHansa Biopharma AB·Filed 2025·Application pending·0 cites
- 0772US2023302100A1Cysteine proteaseHansa Biopharma AB·Filed 2022·Application pending·0 cites
- 0869US2026028608A1Cysteine proteaseHansa Biopharma AB·Filed 2025·Application pending·0 cites
- 0966US12397044B2Method for improving the benefit to a subject of a therapy or therapeutic agentHansa Biopharma AB·Filed 2021·Granted Aug 26, 2025·0 cites·11 claims
- 1062US12460194B2Cysteine proteaseHansa Biopharma AB·Filed 2021·Granted Nov 4, 2025·0 cites·7 claims
- 1156US2026021168A1Conditioning regimen for cell transplantHansa Biopharma AB·Filed 2023·Application pending·0 cites
- 1253US2025325640A1Methods for enhancing adoptive cell transfer immunotherapiesHansa Biopharma AB·Filed 2022·Application pending·0 cites
- 1352US2023181701A1Methods for enhancing adoptive cell transfer immunotherapiesHansa Biopharma AB·Filed 2021·Application pending·0 cites
- 1443US2023110085A1Immunoglobulin detection and associated therapiesHansa Biopharma AB·Filed 2021·Application pending·0 cites
- 1542US2023210962A1Conditioning regimen for transplantHansa Biopharma AB·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →